Posted by Michael Wonder on 29 Mar 2021
TLV subsidises melatonin for children and adolescents with ADHD
26 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, grants a subsidy for the drug Melatonin AGB for children from 6 years up to 17 years of age with ADHD and sleep problems.
The company that markets Melatonin AGB has only applied for the drug to be subsidised for the patient group children and adolescents 6 to 17 years with ADHD and sleep problems where other measures to improve sleep have been insufficient.
TLV can only make decisions for the area of use for which the company has applied. Therefore, the subsidy only applies to this patient group.
